Blood Diagnostics

PRESS RELEASE: Sight Diagnostics Raises $71M To Accelerate Global Expansion of itsFDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer | 8/6/2020

… vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world.” Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight …

Sight Diagnostics raises $71M Series D for its blood analyzer | TechCrunch | 8/5/2020

… gather the data to detect anomalies that may indicate the severity of some of the aspects of the disease. “We just kind of scratched the surface of the ability of AI to help with blood diagnostics ,” said Pollak. “Specifically now, there’s so much value around COVID in decentralizing diagnostics and blood tests. Think keeping people — COVID-negative or -positive — outside of hospitals to reduce the busyness of hospitals and reduce …

Follow Blood Diagnostics:    

Tabletop blood tester Sight Diagnostics raises $71M to expand commercial reach | FierceBiotech | 8/5/2020

… vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, president of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world.” RELATED: Tabletop blood count developer Sight raises $27.8M in series C round The cartridge …

Blood Diagnostics Firm Sight Raises $71M For System That Produces Quick Results | 8/5/2020

… vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world …

Sight Diagnostics hauls in $71M Series D for point-of-care blood analysis | MobiHealthNews | 8/5/2020

… roughly $28 billion by 2026 with a CAGR of 6.6%. It cited advancing tech and the rising awareness of point-of-care diagnostics as key drivers of that growth. Sight’s approach of AI-based blood diagnostics runs parallel to that of 1Drop Diagnostics. This startup, which raised $4.25 million in late 2018 , measures biomarkers from a single drop of blood and delivers a response within roughly 15 minutes via its …

Finger-Prick Blood Analyzer Company Raises $71M | 8/5/2020

… vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, president of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a vision to decentralize information and increase consumer access in healthcare markets across the world.” Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight …

Sight Diagnostics hauls in $71M Series D for fingerprick blood analysis | MobiHealthNews | 8/5/2020

… roughly $28 billion by 2026 with a CAGR of 6.6%. It cited advancing tech and the rising awareness of point-of-care diagnostics as key drivers of that growth. Sight’s approach of AI-based blood diagnostics runs parallel to that of 1Drop Diagnostics. This startup, which raised $4.25 million in late 2018 , measures biomarkers from a single drop of blood and delivers a response within roughly 15 minutes via its …

Workpath Announces 105% Customer Count Growth from Q1 to Q2; Annual Revenue Growth of 50% | PR Newswire | 7/22/2020

RICHMOND, Va. , July 22, Workpath, the only on-demand dispatch and scheduling tech for mobile healthcare teams, is proud to announce a 105% increase in the company’s customer count and a 50% increase in revenue from Q1 to Q2 2020. Platform usage has surged as well. Weekly appointment volume increased 165% since January when the first COVID-19 case was reported in the U.S. Since the launch of the platform …

Better Coronavirus Stock: Grifols or Novartis? | The Motley Fool | 6/19/2020

… company warrants investment? Image source: Getty Images. Grifols takes aim at the COVID-19 plasma therapeutics market Grifols has a lot to offer investors seeking steady growth. With a stable of products ranging from blood diagnostics to infusion-ready IV nutrition bags, the company competes in a handful of different markets, and its pipeline features seven different projects in clinical development. Considering its 11.8% year-over-year revenue growth, Grifols …

Report Study | Impact of COVID-19 on the Global Blood Transfusion Diagnostics Market | 6/8/2020

The new market report on Blood Transfusion Diagnostics is a comprehensive study providing analysis on factors trend and drivers contributing to growth of the Blood Diagnostics . The report is prepared with reference to historic data . Estimation of contribution of segment is expressed in terms of volume and revenue for the forecast period . Market analysis and future prospect is segmented in various sections. Each sections focus on distinct features of the …

5 Reasons to Consider an Alternative to Linux for Your Medical Device | 4/9/2020

… of developers, a rich legacy of source code, and industry-standard POSIX APIs. But Linux may not be the right choice for all projects, especially safety-critical medical devices such as those used in blood diagnostics , ultrasound imaging, infusion delivery, heart monitoring and resuscitation, and robotic surgery. For these demanding applications, the standard Linux kernel can’t deliver the safety-critical capabilities that many medical embedded devices require. While Linux may …

Matternet Unveils New Matternet Station | 3/11/2020

… automated drone delivery into their laboratory and pharmacy operations. The company has been operating in healthcare systems around the world since 2017, replacing slow and expensive on-demand courier services. Hospitals can now move blood diagnostics , pathology specimens and medicine between their facilities and suppliers with secure, extremely fast and predictable aerial delivery. “Our vision is to connect every healthcare facility in every metropolitan area with the fastest transportation method …

Matternet Station to serve as drone delivery hub for hospitals | 3/11/2020

… controlled temperature Matternet The striking Mattenet Station serves as a drone delivery hub for medical packages Matternet 6 / 7 Matternet expects the service to operate around the clock and accommodate the safe transport of blood diagnostics , pathology specimens and medicine Matternet The Matternet Station will serve as a delivery hub for the company’s M2 autonomous drone Matternet View gallery - 7 images Last year, drone logistics company Matternet teamed up with …

Matternet Unveils The New Matternet Station | 3/11/2020

… automated drone delivery into their laboratory and pharmacy operations. The company has been operating in healthcare systems around the world since 2017, replacing slow and expensive on-demand courier services. Hospitals can now move blood diagnostics , pathology specimens and medicine between their facilities and suppliers with secure, extremely fast and predictable aerial delivery. “Our vision is to connect every healthcare facility in every metropolitan area with the fastest transportation method …

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | BioSpace | 12/4/2019

… Alzheimer’s Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation. For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of …

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | 12/2/2019

… Alzheimer’s Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation. For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of …

T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) | Globe Newswire | 11/7/2019

Data will focus on the first RUO assay that can detect 13 resistance genes from both gram-positive and gram-negative pathogens directly from whole blood November 07, 2019 07:30 ET Source: T2 Biosystems, Inc. LEXINGTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ: TTOO ), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will be highlighting its …

Laser Technology Cuts Critical Blood Incubation Time | 10/18/2019

… the current standard of five minutes to just 40 seconds. Developed by researchers at the Bioresource Processing Institute of Australia (BioPRIA), located within the Department of Chemical Engineering at Monash University — in conjunction with blood diagnostics manufacturer Haemokinesis Pty. Ltd. — the technology is the first of its kind and could bring pretransfusion testing out of the pathology lab and into point of care. Blood transfusion is a critical treatment for …

T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019 | Markets Insider | Business Insider | 6/20/2019

LEXINGTON, Mass., June 20, 2019 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24. “The T2Bacteria® and T2Candida ® panels are the first-and-only …

T2 Biosystems Highlights Current and Future Opportunities for its Breakthrough Rapid Diagnostic Technology for Biothreat Pathogen Detection | Globe Newswire | 6/17/2019

June 17, 2019 07:30 ET Source: T2 Biosystems, Inc. Data on T2Candida auris research-use-only demonstrates 5-hour time-to-result versus 14-days with blood culture T2MR Technology demonstrates high sensitivity for the detection of biothreat pathogens LEXINGTON, Mass., June 17, 2019 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ: TTOO ), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, announced today …

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

… own experience, maybe not at the same scale, but there are still a lot of people who build technology companies who are trying to do it the right way.” ‘The Wild Wild West of blood diagnostics ’ The University of California, Berkeley alumna began working at Theranos in her early 20s — and, as she recalled in Gibney’s documentary, quickly “drank the Kool-Aid” after joining the medical-device startup. Holmes had …

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

Worldwide Offices Facebook Senior Executive Kevin Lo Joins Genalyte As President Former Facebook and Google executive joins the biotech company transforming blood diagnostics and data for point of care decision support News provided by 12:08 ET Share this article SAN DIEGO , Dec. 14, 2017 /PRNewswire-USNewswire/ – Genalyte, Inc. announced today that Kevin Lo has been named President of the company. Lo comes to Genalyte following leading roles at Facebook and …

GE Ventures unveils new blood collection startup Drawbridge Health | TechCrunch | 11/29/2017

… Diagnostics or Lab Corp. Instead, the device can stay in the clinic and the proprietary Drawbridge cartridge holding your blood would be shipped out to the third-party lab for results. Of course, any blood diagnostics startup claiming to collect just a few drops of blood for testing on a small device is going to get compared to Theranos, which first promised to deliver results for hundreds of diseases on …

Plaxgen Plaque Array Lipid-Modifying Drugs Study Published in Journal of Visualized Experiments | PR Newswire | 11/13/2017

… changing cholesterol particle shape, could be key factor in drug efficacy and drug matching News provided by 08:35 ET Share this article FREMONT, Calif. , Nov. 13, 2017 /PRNewswire/ – Plaxgen, Inc., developing flow cytometry-based blood diagnostics for plaque-associated diseases, such as atherosclerosis and Alzheimer’s, announced that new research exploring the effect of lipid-lowering drugs, including statins, on the morphology of cholesterol particles in human serum samples was published …

Heska’s (HSKA) CEO Kevin Wilson on Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 11/3/2017

… Kevin Wilson Thanks, Brett, and good morning, everyone. Today we report third quarter that shows continued strong execution in the core of our playbook, including 16% growing in our largest and key business of blood diagnostics subscriptions. Consolidated gross margin expansion of 210 basis points to 43.1%. Strong market share gains and nice growth in our cash providing from operations which is outstripped all of 2016 and best the first …

Rapid Diagnostics

T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) | Globe Newswire | 11/7/2019

… blood Diagnostics in Enabling Changes in Clinical Decisions and Improving Outcomes,” on November 8 at 9:25 a.m. “Antimicrobial resistance is no longer an emerging threat – it is a very real, clear and present danger to public health, making it important for professionals in the infectious disease industry to seriously consider all types of solutions to this issue. These solutions include, among others, rapid diagnostics of bloodstream infections and rapid resistance …

T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) | Benzinga | 11/7/2019

… blood Diagnostics in Enabling Changes in Clinical Decisions and Improving Outcomes,” on November 8 at 9:25 a.m. “Antimicrobial resistance is no longer an emerging threat – it is a very real, clear and present danger to public health, making it important for professionals in the infectious disease industry to seriously consider all types of solutions to this issue. These solutions include, among others, rapid diagnostics of bloodstream infections and rapid resistance …

Medicare

OTC/DTC Infectious Disease Diagnostics Markets, 2019 & 2020-2024: Privacy and Technology Create New Markets for Infectious Disease Testing / Multiplex Changes the Competitive Landscape | PR Newswire | 10/31/2019

… evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. The report has hundreds of pages of information including a complete list of Current 2019 United States Medicare Fee Payment Schedules to help sharpen your pricing. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. Key …

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

… so paranoid about Theranos and them spying on me, I had a burner phone just to call the Centers for Medicare and Medicaid Services.’ “Being followed is a very terrifying thing,” 28-year-old Cheung … do it the right way.” ‘The Wild Wild West of blood diagnostics’ The University of California, Berkeley alumna began working at Theranos in her early 20s — and, as she recalled in Gibney’s documentary, quickly “drank …

Clinical Data

T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019 | Markets Insider | Business Insider | 6/20/2019

Blood Diagnostics that Enable Changes in Clinical Decisions, on Friday, June 21 from 12:00 – 12:45 pm in Theater North in the Exhibit Hall of The George R. Moscone Convention Center. The presentation will highlight clinical updates regarding current and future applications of T2 technology, including: T2Bacteria provides actionable clinical information: New T2Bacteria Panel clinical data being generated by independent commercial users shows its ability to benefit tested patients in the …

T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019 | Globe Newswire | 6/20/2019

T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019 Real-world data to highlight substantial impact T2Bacteria® has made on patient outcomes June 20 … Biosystems, will present an Industry Education Workshop, Rapid, Direct-from-Blood Diagnostics that Enable Changes in Clinical Decisions, on Friday, June 21 from 12:00 – 12:45 pm in Theater North in the Exhibit Hall of The …

Patient Safety

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

… of people who build technology companies who are trying to do it the right way.” ‘The Wild Wild West of blood diagnostics’ The University of California, Berkeley alumna began working at Theranos in her early … in herself and in her commitment to scientific integrity and patient safety. “It could have been a little less painful, I think, if I started really clearly with just: ‘Look, stay calm, you are fine …

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

… results.’ But Cheung would soon come to discover that Theranos was, as she put it, “the Wild Wild West of blood diagnostics.” She started in research and development, but got transferred to the clinical lab … in herself and in her commitment to scientific integrity and patient safety. “It could have been a little less painful, I think, if I started really clearly with just: ‘Look, stay calm, you are fine …

Diagnostic Tests

Heska’s (HSKA) CEO Kevin Wilson on Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 11/3/2017

… shows continued strong execution in the core of our playbook, including 16% growing in our largest and key business of blood diagnostics subscriptions. Consolidated gross margin expansion of 210 basis points to 43.1%. Strong market … blood diagnostic instruments and consumables, single-use pharmaceuticals, vaccines and diagnostic tests, which we referred to as PVD and sales of digital imaging products. Revenue from our key core blood diagnostics continues to grow strongly …

Heska Reports Third Quarter Results | PR Newswire | 11/2/2017

… The Company posted third quarter revenue of $31.4 million compared to $33.4 million in the third quarter of 2016. Core blood diagnostics revenue rose 16%, offset by an expected 32% decline in revenue from Other … and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on supporting veterinarians in the canine and feline healthcare space. For further information on …

Biogen Inc.

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | BioSpace | 12/4/2019

Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation. For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential …

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | 12/2/2019

Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential disease …

Biogen

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | BioSpace | 12/4/2019

Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation. For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential …

Eisai to Present Latest Data on Alzheimer’s Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer’s Disease Conference | 12/2/2019

Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential disease …

T2 Biosystems

T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) | Globe Newswire | 11/7/2019

… resistance genes from both gram-positive and gram-negative pathogens directly from whole blood November 07, 2019 07:30 ET Source: T2 Biosystems, Inc. LEXINGTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ: TTOO … the keynote address, titled, “The Impact of Rapid, Direct-from-blood Diagnostics in Enabling Changes in Clinical Decisions and Improving Outcomes,” on November 8 at 9:25 a.m. “Antimicrobial resistance is no longer an emerging threat …

T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) | Benzinga | 11/7/2019

LEXINGTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ: TTOO ), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will be highlighting its … the keynote address, titled, “The Impact of Rapid, Direct-from-blood Diagnostics in Enabling Changes in Clinical Decisions and Improving Outcomes,” on November 8 at 9:25 a.m. “Antimicrobial resistance is no longer an emerging threat …

Genalyte

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

Worldwide Offices Facebook Senior Executive Kevin Lo Joins Genalyte As President Former Facebook and Google executive joins the biotech company transforming blood diagnostics and data for point of care decision support News provided by 12:08 ET Share this article SAN DIEGO , Dec. 14, 2017 /PRNewswire-USNewswire/ – Genalyte, Inc. announced today that Kevin Lo has been named President of the company. Lo comes to Genalyte following leading roles at Facebook and …

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

SAN DIEGO , Dec. 14, 2017 /PRNewswire-USNewswire/ – Genalyte, Inc. announced today that Kevin Lo has been named President of the company. Lo comes to Genalyte following leading roles at Facebook and Google. He previously served … outcomes,” said Lo. “The novel approach using the company’s breakthrough blood diagnostics technology and cloud lab model enables rapid, accurate point of care decisions. I’m excited to join the Genalyte team and help deliver this …

Navisite

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

… Offices Facebook Senior Executive Kevin Lo Joins Genalyte As President Former Facebook and Google executive joins the biotech company transforming blood diagnostics and data for point of care decision support News provided by 12:08 ET … dual roles as CFO and COO leading the turnaround of Navisite Inc. A former strategy consultant at Bain & Co, Lo got his start in software programming as a research assistant at NASA’s Jet Propulsion Laboratory …

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

blood diagnostics technology and cloud lab model enables rapid, accurate point of care decisions. I’m excited to join the Genalyte team and help deliver this transformative technology to the health care system.” Lo has a long history of success in endeavors across the tech and telecom space, including his earlier tenures as COO of M2Z Networks, and his dual roles as CFO and COO leading the turnaround of Navisite Inc …

Erika Cheung

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

Even now, Erika Cheung can get a little nervous about being followed. The occasional unease is the lingering aftereffect of the former Theranos lab associate’s role in exposing the now-defunct health-care startup, which … do it the right way.” ‘The Wild Wild West of blood diagnostics’ The University of California, Berkeley alumna began working at Theranos in her early 20s — and, as she recalled in Gibney’s documentary, quickly “drank …

Theranos whistleblower: How to prevent another $600M Silicon Valley disaster - MarketWatch | 5/15/2019

Even now, Erika Cheung can get a little nervous about being followed. The occasional unease is the lingering aftereffect of the former Theranos lab associate’s role in exposing the now-defunct health-care startup, which … was, as she put it, “the Wild Wild West of blood diagnostics.” She started in research and development, but got transferred to the clinical lab. Amid a workplace rife with fear, stress and long work …

Kevin Lo

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

Worldwide Offices Facebook Senior Executive Kevin Lo Joins Genalyte As President Former Facebook and Google executive joins the biotech company transforming blood diagnostics and data for point of care decision support News provided by 12:08 ET Share this article SAN DIEGO , Dec. 14, 2017 /PRNewswire-USNewswire/ – Genalyte, Inc. announced today that Kevin Lo has been named President of the company. Lo comes to Genalyte following leading roles at Facebook and …

Facebook Senior Executive Kevin Lo Joins Genalyte As President | PR Newswire | 12/14/2017

SAN DIEGO , Dec. 14, 2017 /PRNewswire-USNewswire/ – Genalyte, Inc. announced today that Kevin Lo has been named President of the company. Lo comes to Genalyte following leading roles at Facebook and Google. He previously served … outcomes,” said Lo. “The novel approach using the company’s breakthrough blood diagnostics technology and cloud lab model enables rapid, accurate point of care decisions. I’m excited to join the Genalyte team and help deliver this …